Purpose: To evaluate the efficacy and safety of 0.1 mmol/kg gadodiamide administration for contrast-enhanced magnetic resonance angiography (MRA) in detecting hemodynamically relevant renal artery stenosis (RAS) when compared with intraarterial digital subtraction angiography (IA-DSA) as the gold standard.
Materials And Methods: In a multicenter, controlled study, 395 patients with suspected or known RAS were included. Three independent readers evaluated the MRA images. Two readers evaluated the IA-DSA images and subsequently achieved consensus. The sensitivities and specificities of gadodiamide-enhanced MRA were analyzed at the per-patient and per-vessel levels (exact 1-sided binomial test at alpha = 0.025 with 95% confidence interval).
Results: A total of 335 patients who had available standard of truth and MRA tests were included in the all-subjects efficacy population: 55.5% (186/335) men and 44.5% women with a mean age of 63 +/- 13 years (range 17-85 years). The sensitivities and specificities ranged from 81% to 86% for all independent readers at the per-patient analysis based on subjects with the diagnostic images. Similar results were achieved with per-vessel level analysis. Fewer than 1% of patients had adverse event associated with gadodiamide administration. There were no cases of nephrogenic systemic fibrosis (NSF) reported.
Conclusion: Gadodiamide administration at the labeled dose of 0.1 mmol/kg for contrast-enhanced MRA achieved equivalent results compared to IA-DSA in evaluation of RAS and was well tolerated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jmri.22032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anaphylactic risk associated with iodinated and gadolinium-based contrast media.
Expert Opin Drug Saf
November 2024
Department of Radiology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Background: This study aimed to analyze the risk signals of iodinated and gadolinium-based contrast media associated with anaphylaxis.
Research Design And Methods: Data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) were retrospectively reviewed from January 2004 to September 2022. Disproportionality and Bayesian analyses were used in data mining to screen for suspected anaphylaxis using contrast media.
Identification of potential therapeutic targets for nonischemic cardiomyopathy in European ancestry: an integrated multiomics analysis.
Cardiovasc Diabetol
September 2024
Key Laboratory of Tropical Translational Medicine of Ministry of Education & Key Laboratory for Tropical Cardiovascular Diseases Research of Hainan Province, School of Public Health, Hainan Medical University, Haikou, 571199, China.
Background: Nonischemic cardiomyopathy (NISCM) is a clinical challenge with limited therapeutic targets. This study aims to identify promising drug targets for NISCM.
Methods: We utilized cis-pQTLs from the deCODE study, which includes data from 35,559 Icelanders, and SNPs from the FinnGen study, which includes data from 1,754 NISCM cases and 340,815 controls of Finnish ancestry.
The safety of magnetic resonance imaging contrast agents.
Front Toxicol
August 2024
Kidney Institute of New Mexico, University of New Mexico Health Science Center, Kidney Institute of New Mexico, Albuquerque, NM, United States.
Article Synopsis
- Gadolinium-based contrast agents are commonly used in medical imaging but have been linked to health issues like nephrogenic systemic fibrosis and encephalopathy after exposure.
- These agents are designed to bind gadolinium tightly to minimize toxicity, but there's concern that uncoupled gadolinium could be harmful.
- Recent research from the Kidney Institute of New Mexico discovered gadolinium-rich nanoparticles in human kidney cells, suggesting these particles may contribute to long-term toxicity from contrast agents.
Deposition of Gadolinium in the Central and Peripheral Nervous Systems and Its Effects on Sensory, Cognitive, and Athletic Implications after Multiple Injections of Gadolinium-Based Contrast Agents in Rats.
AJNR Am J Neuroradiol
August 2024
From the Department of Neurosurgery (X.Y., X.L., J.S, G.D., J.K., W.F., Y.H., X.T., E.C.), Zhongshan Hospital of Xiamen University, School of Medcine, Xiamen University, XiaMen, China.
Background And Purpose: After repeat administration of gadolinium-based contrast agents (GBCAs), the association between gadolinium retention in the central and peripheral nervous systems and the main manifestations of myelopathy and progressive neurologic symptoms remains unclear. We investigated the effects of the repeat administration of GBCAs on gadolinium retention in the central and peripheral nervous systems and the sensory, cognitive, and athletic implications.
Materials And Methods: Forty-eight male Wistar rats (6 weeks of age) were randomly divided into 4 experimental groups (12 rats in each group): the gadodiamide group (linear and nonionic GBCAs), the gadopentetate dimeglumine group (linear and ionic GBCAs), the gadoterate meglumine group (macrocyclic and ionic GBCAs), and the control group (0.
Assessing teratogenic risks of gadolinium in freshwater environments: Implications for environmental health.
Ecotoxicol Environ Saf
June 2024
Department of Sciences, University of Roma Tre, Viale G. Marconi 446, Rome 00146, Italy; National Biodiversity Future Center (NBFC), Università di Palermo, Piazza Marina 61, Palermo 90133, Italy.
Gadolinium (Gd) is among the rare earth elements extensively utilized in both industrial and medical applications. The latter application appears to contribute to the rise in Gd levels in aquatic ecosystems, as it is excreted via urine from patients undergoing MRI scans and often not captured by wastewater treatment systems. The potential environmental and biological hazards posed by gadolinium exposure are still under investigation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!